Stock IMUX IMMUNIC, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Immunic, Inc.

Equities

IMUX

US4525EP1011

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
1.37 USD +3.01% Intraday chart for Immunic, Inc. +12.30% -8.67%
04-30 Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation CI
04-09 Transcript : Immunic, Inc. - Special Call

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
AQ
Immunic Announces Publication of Extended Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology and Neuroinflammation
AQ
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
PR
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
CI
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
AQ
Transcript : Immunic, Inc. - Special Call
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
PR
Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium
MT
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
AQ
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
AQ
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
PR
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
AQ
Immunic to Participate in Investor and Scientific Conferences in March
PR
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
PR
Wedbush Adjusts Immunic's PT to $4 From $7 on Increased Sharecount From First Tranche of Private Placemebt, Keeps Outperform Rating
MT
Immunic reports successful 2023 and prepares for key 2025 milestones
AQ
Transcript : Immunic, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
PR
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMUX Stock
  4. News Immunic, Inc.